RT-002 achieved "a trifecta of positive clinical results," Revance Therapeutics Inc. CEO Dan Browne said, pointing to across-the-board success in a pair of phase III trials with next-generation neuromodulator DaxibotulinumtoxinA for injection (RT-002), which turned up positive top-line results in alleviating moderate to severe glabellar (frown) lines in the clinical program called Sakura.